Exact Sciences has acquired U.S. rights to Freenome’s colorectal cancer blood test for $75 million upfront, positioning itself against market rival Guardant Health in the liquid biopsy segment. The partnership aims to expand access to non-invasive colorectal cancer screening tools and leverage the growing liquid biopsy market. This strategic move enhances Exact Sciences’ portfolio and addresses increasing demand for early cancer detection technologies.